Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: Experience with 1,000 patients

Marino Cimitan, Laura Evangelista, Marina Hodolič, Giuliano Mariani, Tanja Baseric, Valentina Bodanza, Giorgio Saladini, Duccio Volterrani, Anna Rita Cervino, Michele Gregianin, Giulia Puccini, Federica Guidoccio, Jure Fettich, Eugenio Borsatti

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The objective of this study was to explore the ability of the initial Gleason score (GS) to predict the rate of detection of recurrent prostate cancer (PCa) with 18F-Choline PET/CT in a large cohort of patients. Methods: Data from 1,000 patients who had undergone 18F-Choline PET/CT because of biochemical evidence of relapse of PCa between 2004 and 2013 were retrieved from databases at 4 centers. Continuous data were compared by the Student t test or ANOVA, and categoric variables were compared by the χ2 test. Univariable and multivariable analyses were performed by logistic regression. Results: The GS at diagnosis was less than or equal to 6 in 257 patients, 7 in 347 patients, and greater than 7 in 396 patients. The results of 645 PET/CT scans were positive for PCa recurrence. Eighty-one percent of the positive PET/CT results were found in patients with a PSA level of greater than or equal to 2 ng/mL, 43% were found in patients with a PSA level of 1-2 ng/mL, and 31% were found in patients with a PSA level of less than or equal to 1 ng/mL; 78.8% of patients with positive PET/CT results had a GS of greater than 7. The results of 18F-Choline PET/CT scans were negative in 300 patients; 44% had a GS of less than or equal to 6, 35% had a GS of 7, and 17% had a GS of greater than 7. PET/CT results were rated as doubtful in only 5.5% of patients (median PSA, 1.8 ng/mL). When the GS was greater than 7, the rates of detection of 18F-Choline PET/CT were 51%, 65%, and 91% for a PSA level of less than 1 ng/mL, 1-2 ng/mL, and greater than 2 ng/mL, respectively. In univariable and multivariable analyses, both a GS of 7 and a GS of greater than 7 were independent predictors for positive 18F-Choline PET/CT results (odds ratios, 0.226 and 0.330, respectively; P values for both, 18F-Choline PET/CT scan results for recurrent PCa, even when the PSA level is low (i.e., ≤1 ng/mL).

Original languageEnglish
Pages (from-to)209-215
Number of pages7
JournalJournal of Nuclear Medicine
Volume56
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Neoplasm Grading
Prostatic Neoplasms
Recurrence
fluoromethylcholine
Analysis of Variance
Logistic Models
Odds Ratio
Databases
Students

Keywords

  • F-choline PET
  • Gleason score
  • Prostate cancer
  • PSA
  • Restaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer : Experience with 1,000 patients. / Cimitan, Marino; Evangelista, Laura; Hodolič, Marina; Mariani, Giuliano; Baseric, Tanja; Bodanza, Valentina; Saladini, Giorgio; Volterrani, Duccio; Cervino, Anna Rita; Gregianin, Michele; Puccini, Giulia; Guidoccio, Federica; Fettich, Jure; Borsatti, Eugenio.

In: Journal of Nuclear Medicine, Vol. 56, No. 2, 01.02.2015, p. 209-215.

Research output: Contribution to journalArticle

Cimitan, Marino ; Evangelista, Laura ; Hodolič, Marina ; Mariani, Giuliano ; Baseric, Tanja ; Bodanza, Valentina ; Saladini, Giorgio ; Volterrani, Duccio ; Cervino, Anna Rita ; Gregianin, Michele ; Puccini, Giulia ; Guidoccio, Federica ; Fettich, Jure ; Borsatti, Eugenio. / Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer : Experience with 1,000 patients. In: Journal of Nuclear Medicine. 2015 ; Vol. 56, No. 2. pp. 209-215.
@article{feaf79941b89400782079baa1a0c8bc4,
title = "Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: Experience with 1,000 patients",
abstract = "The objective of this study was to explore the ability of the initial Gleason score (GS) to predict the rate of detection of recurrent prostate cancer (PCa) with 18F-Choline PET/CT in a large cohort of patients. Methods: Data from 1,000 patients who had undergone 18F-Choline PET/CT because of biochemical evidence of relapse of PCa between 2004 and 2013 were retrieved from databases at 4 centers. Continuous data were compared by the Student t test or ANOVA, and categoric variables were compared by the χ2 test. Univariable and multivariable analyses were performed by logistic regression. Results: The GS at diagnosis was less than or equal to 6 in 257 patients, 7 in 347 patients, and greater than 7 in 396 patients. The results of 645 PET/CT scans were positive for PCa recurrence. Eighty-one percent of the positive PET/CT results were found in patients with a PSA level of greater than or equal to 2 ng/mL, 43{\%} were found in patients with a PSA level of 1-2 ng/mL, and 31{\%} were found in patients with a PSA level of less than or equal to 1 ng/mL; 78.8{\%} of patients with positive PET/CT results had a GS of greater than 7. The results of 18F-Choline PET/CT scans were negative in 300 patients; 44{\%} had a GS of less than or equal to 6, 35{\%} had a GS of 7, and 17{\%} had a GS of greater than 7. PET/CT results were rated as doubtful in only 5.5{\%} of patients (median PSA, 1.8 ng/mL). When the GS was greater than 7, the rates of detection of 18F-Choline PET/CT were 51{\%}, 65{\%}, and 91{\%} for a PSA level of less than 1 ng/mL, 1-2 ng/mL, and greater than 2 ng/mL, respectively. In univariable and multivariable analyses, both a GS of 7 and a GS of greater than 7 were independent predictors for positive 18F-Choline PET/CT results (odds ratios, 0.226 and 0.330, respectively; P values for both, 18F-Choline PET/CT scan results for recurrent PCa, even when the PSA level is low (i.e., ≤1 ng/mL).",
keywords = "F-choline PET, Gleason score, Prostate cancer, PSA, Restaging",
author = "Marino Cimitan and Laura Evangelista and Marina Hodolič and Giuliano Mariani and Tanja Baseric and Valentina Bodanza and Giorgio Saladini and Duccio Volterrani and Cervino, {Anna Rita} and Michele Gregianin and Giulia Puccini and Federica Guidoccio and Jure Fettich and Eugenio Borsatti",
year = "2015",
month = "2",
day = "1",
doi = "10.2967/jnumed.114.141887",
language = "English",
volume = "56",
pages = "209--215",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "2",

}

TY - JOUR

T1 - Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer

T2 - Experience with 1,000 patients

AU - Cimitan, Marino

AU - Evangelista, Laura

AU - Hodolič, Marina

AU - Mariani, Giuliano

AU - Baseric, Tanja

AU - Bodanza, Valentina

AU - Saladini, Giorgio

AU - Volterrani, Duccio

AU - Cervino, Anna Rita

AU - Gregianin, Michele

AU - Puccini, Giulia

AU - Guidoccio, Federica

AU - Fettich, Jure

AU - Borsatti, Eugenio

PY - 2015/2/1

Y1 - 2015/2/1

N2 - The objective of this study was to explore the ability of the initial Gleason score (GS) to predict the rate of detection of recurrent prostate cancer (PCa) with 18F-Choline PET/CT in a large cohort of patients. Methods: Data from 1,000 patients who had undergone 18F-Choline PET/CT because of biochemical evidence of relapse of PCa between 2004 and 2013 were retrieved from databases at 4 centers. Continuous data were compared by the Student t test or ANOVA, and categoric variables were compared by the χ2 test. Univariable and multivariable analyses were performed by logistic regression. Results: The GS at diagnosis was less than or equal to 6 in 257 patients, 7 in 347 patients, and greater than 7 in 396 patients. The results of 645 PET/CT scans were positive for PCa recurrence. Eighty-one percent of the positive PET/CT results were found in patients with a PSA level of greater than or equal to 2 ng/mL, 43% were found in patients with a PSA level of 1-2 ng/mL, and 31% were found in patients with a PSA level of less than or equal to 1 ng/mL; 78.8% of patients with positive PET/CT results had a GS of greater than 7. The results of 18F-Choline PET/CT scans were negative in 300 patients; 44% had a GS of less than or equal to 6, 35% had a GS of 7, and 17% had a GS of greater than 7. PET/CT results were rated as doubtful in only 5.5% of patients (median PSA, 1.8 ng/mL). When the GS was greater than 7, the rates of detection of 18F-Choline PET/CT were 51%, 65%, and 91% for a PSA level of less than 1 ng/mL, 1-2 ng/mL, and greater than 2 ng/mL, respectively. In univariable and multivariable analyses, both a GS of 7 and a GS of greater than 7 were independent predictors for positive 18F-Choline PET/CT results (odds ratios, 0.226 and 0.330, respectively; P values for both, 18F-Choline PET/CT scan results for recurrent PCa, even when the PSA level is low (i.e., ≤1 ng/mL).

AB - The objective of this study was to explore the ability of the initial Gleason score (GS) to predict the rate of detection of recurrent prostate cancer (PCa) with 18F-Choline PET/CT in a large cohort of patients. Methods: Data from 1,000 patients who had undergone 18F-Choline PET/CT because of biochemical evidence of relapse of PCa between 2004 and 2013 were retrieved from databases at 4 centers. Continuous data were compared by the Student t test or ANOVA, and categoric variables were compared by the χ2 test. Univariable and multivariable analyses were performed by logistic regression. Results: The GS at diagnosis was less than or equal to 6 in 257 patients, 7 in 347 patients, and greater than 7 in 396 patients. The results of 645 PET/CT scans were positive for PCa recurrence. Eighty-one percent of the positive PET/CT results were found in patients with a PSA level of greater than or equal to 2 ng/mL, 43% were found in patients with a PSA level of 1-2 ng/mL, and 31% were found in patients with a PSA level of less than or equal to 1 ng/mL; 78.8% of patients with positive PET/CT results had a GS of greater than 7. The results of 18F-Choline PET/CT scans were negative in 300 patients; 44% had a GS of less than or equal to 6, 35% had a GS of 7, and 17% had a GS of greater than 7. PET/CT results were rated as doubtful in only 5.5% of patients (median PSA, 1.8 ng/mL). When the GS was greater than 7, the rates of detection of 18F-Choline PET/CT were 51%, 65%, and 91% for a PSA level of less than 1 ng/mL, 1-2 ng/mL, and greater than 2 ng/mL, respectively. In univariable and multivariable analyses, both a GS of 7 and a GS of greater than 7 were independent predictors for positive 18F-Choline PET/CT results (odds ratios, 0.226 and 0.330, respectively; P values for both, 18F-Choline PET/CT scan results for recurrent PCa, even when the PSA level is low (i.e., ≤1 ng/mL).

KW - F-choline PET

KW - Gleason score

KW - Prostate cancer

KW - PSA

KW - Restaging

UR - http://www.scopus.com/inward/record.url?scp=84922016267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922016267&partnerID=8YFLogxK

U2 - 10.2967/jnumed.114.141887

DO - 10.2967/jnumed.114.141887

M3 - Article

C2 - 25552670

AN - SCOPUS:84922016267

VL - 56

SP - 209

EP - 215

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 2

ER -